Guardian Pharmacy Services (GRDN) Q4 2024 Earnings Call March 26, 2025 10:35 PM ET Company Participants Fred Burke - CEO, President & DirectorDavid Morris - CFO, Executive VP & DirectorParker Snure - Senior Equity Research AssociateRaj Kumar - Senior Research Associate Conference Call Participants David Macdonald - Analyst Operator Good day, everyone, and welcome to Guardian Pharmacy's Fourth Quarter and Full Year twenty twenty four Earnings Call. At this time, all participants are on a listen only mode. La ...

Oxbridge Re Holdings Limited (NASDAQ:OXBR) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Wrendon Timothy - Chief Financial Officer & Corporate Secretary Jay Madhu - Chairman, President & Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group Kent Engelke - Capitol Securities Operator Good afternoon. Welcome to Oxbridge Re's Fiscal 2024 Earnings Conference Call. My name is Matt, and I'll be your conference operator this afternoon. At this time, all par ...

Usio (USIO) Q4 2024 Earnings Call March 26, 2025 09:48 PM ET Company Participants Paul Manley - SVP, IRLouis Hoch - Chairman and CEOGreg Carter - EVP, Payment Acceptance Conference Call Participants Scott Buck - Managing Director & Senior Technology Analyst Operator Hello, and welcome to the UCO's Fourth Quarter and Fiscal Year End twenty twenty four Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please als ...

Financial Data and Key Metrics Changes - In Q4 2024, the company reported revenue of $1.55 billion, aligning with prior outlook, and adjusted EBITDA of $96.1 million, exceeding expectations [13][44] - Gross profit decreased by approximately 3% to $589 million, primarily due to the loss of the fifty-third week in 2024, while gross margin increased by 180 basis points to 38% [43][44] - Total SG&A expenses were $571.9 million, or 36.8% of net sales, an increase of about 60 basis points year-over-year [44] Business Line Data and Key Metrics Changes - The services segment is identified as the fastest-growing area within the pet category, with the company holding an established leadership position [11] - The company is focusing on optimizing existing vet hospitals to drive services growth and improve margins with minimal capital investment [39] Market Data and Key Metrics Changes - The pet category is projected to reach $200 billion in the next five years, driven by the ongoing humanization of pets [11] - The company closed 25 net locations in 2024 and anticipates closing an additional 20 to 30 locations in 2025 [49][122] Company Strategy and Development Direction - The company is implementing a phased approach to restore profitability, focusing on improving the operating model, enhancing retail fundamentals, and optimizing product assortment [14][20] - The leadership team is committed to driving gross margin improvement and leveraging SG&A to enhance the economic model [41][42] - Future growth initiatives will include enhancing omnichannel capabilities and investing in services opportunities [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to long-term profitable growth, emphasizing the importance of operational improvements and cost control [32][52] - The outlook for 2025 anticipates overall net sales to decline low single digits compared to the previous year, with adjusted EBITDA expected between $375 and $390 million [48][49] Other Important Information - The company aims to achieve a debt-to-EBITDA leverage ratio below two times, focusing on profitability improvement [45] - Management is closely monitoring potential tariff impacts, particularly on inventory purchases from China, Canada, and Mexico, which represent only about 5% of total merchandise costs [46][47] Q&A Session Summary Question: What infrastructure investments are needed for phase three? - Management indicated that no significant infrastructure investments are required, focusing instead on improving EBITDA through disciplined operations [59][60] Question: What are the low-hanging fruit for EBITDA improvement? - Management highlighted the importance of gross margin expansion and leveraging SG&A as key areas for improvement [67][70] Question: How does the company plan to manage SG&A amid declining sales? - Management emphasized that SG&A leverage is about efficiency and effectiveness, ensuring customer needs are met without compromising service [86][87] Question: What is the company's approach to pricing and promotions? - Management stated that they are focused on rational pricing strategies and avoiding excessive promotional stacking to enhance profitability [151][153] Question: How does the company view the competitive landscape and market share? - Management acknowledged the need to sacrifice some sales for improved profitability but expressed confidence in regaining market share through operational improvements [80][84]

Financial Data and Key Metrics Changes - Total revenues in 2024 were $2 million, a decrease from $2.6 million in 2023, and $0.5 million for the fourth quarter of 2024 compared to $0.9 million for the prior year [5] - R&D expenses were $10.4 million in 2024, down from $29.4 million in the prior year, with fourth quarter expenses at $1.9 million compared to $5.6 million in 2023 [6] - SG&A expenses were $10 million in 2024, compared to $12.7 million in the prior year, and $2 million for the fourth quarter of 2024 compared to $2.2 million for the prior year [7] - Cash and investments at the end of 2024 were $12 million, down from $29.8 million at the end of 2023, with sufficient funds to support operations through the third quarter of 2025 [8] Business Line Data and Key Metrics Changes - The decrease in revenues was attributed to lower earn-out revenue from Indivior, reduced revenue from feasibility agreements, and lower sales of excipients [6] Company Strategy and Development Direction - The company completed the sale of the Allset product line in the fourth quarter of 2024, using proceeds to repay its term loan, resulting in a debt-free status [9] - The focus is on developing larsucosterol for alcohol-associated hepatitis, with plans to explore funding options through strategic partnerships and capital markets [10] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significant mortality associated with alcohol-associated hepatitis, with larsucosterol showing nearly 60% reductions in mortality in Phase 2b trials [11][13] - The FDA granted breakthrough therapy designation for larsucosterol, and the company is committed to advancing its Phase 3 trial, expecting to report top-line data in approximately two years [14][15] Other Important Information - The company is actively exploring strategic partnerships and business development opportunities to support the Phase 3 study [38] Q&A Session Summary Question: Estimated cost of the Phase 3 trial - The estimated cost for the Phase 3 trial is approximately $20 million [18] Question: Clarification on hospitalization to first dose variations - Management explained the importance of timely intervention, noting that in the US, patients are typically treated within four days, while in poorer performing regions, it can take up to two weeks [30] Question: Updates on potential strategic partnerships - The company is actively exploring various possibilities for partnerships to advance the product, though specifics could not be disclosed [38] Question: Possibility of a smaller Phase 2b study - Management indicated that conducting a Phase 3 trial is more efficient than a smaller Phase 2b study, given the need for a larger patient cohort [46] Question: Opportunities for non-funded studies in ex-US countries - There is potential for conducting regional studies with ex-US partners, although the current focus remains solely on alcohol-associated hepatitis [50]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $164,000, a decrease from $299,000 in Q4 2023, primarily due to lower sales of RH collagen products [16] - GAAP revenue for the full year 2024 was $515,000, significantly down from $11 million in 2023, largely due to a $10 million milestone payment received in 2023 from AbbVie [16][21] - GAAP gross loss for Q4 2024 was $108,000 compared to a gross loss of $474,000 in Q4 2023, while the gross loss for the full year 2024 was $1.1 million compared to a gross profit of $9 million in 2023 [18][21] - GAAP net loss for Q4 2024 was $3.9 million or $0.34 per share, compared to a net loss of $4.7 million or $0.41 per share in Q4 2023; for the full year, the net loss was $16.6 million or $1.45 per share, compared to a net loss of $7 million or $0.62 per share in 2023 [21] Business Line Data and Key Metrics Changes - The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a 10% CAGR [8] - The regenerative breast implant program is advancing preclinical testing with promising outcomes observed in tissue integration and vascularization [12][13] - Collaboration with AbbVie is ongoing, with AbbVie currently reviewing interim results from clinical trials initiated in 2023 [10][29] Market Data and Key Metrics Changes - The market potential for the VerGenix STR product, aimed at treating tendon injuries, is estimated to be between 1% to 3% of the population [33] - The company is establishing distribution networks in Europe and Asia for the VerGenix product, with expectations for market penetration following regulatory approvals [33][34] Company Strategy and Development Direction - The company aims to be a leader in regenerative medicine, focusing on proprietary programs and potential collaborations [6][8] - Plans include launching clinical trials for the photocurable dermal filler within two years and optimizing the regenerative breast implant for clinical readiness [43] - Expansion of the distribution network for VerGenix STR and broadening product offerings for bioinks are also key strategic initiatives [44] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of transparency regarding upcoming catalysts and the stability of the company's cash position, which is expected to support operations through Q2 2026 [40][41] - The company is aware of macroeconomic conditions affecting share price but maintains a stable operational outlook [41] Other Important Information - Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an additional $2 million received from AbbVie in February 2025 [22][23] - The company has implemented cost reduction plans that do not materially impact main development programs [39] Q&A Session Summary Question: When will there be an update from AbbVie on the studies and potential milestone payments in 2025? - AbbVie is currently collecting data and reviewing interim results from clinical trials; the timeline for updates is controlled by AbbVie [29][30] Question: What is the market potential for the VerGenix product and expected revenue flow? - The VerGenix product targets tendon injuries with a market potential of 1% to 3% of the population; the company is in the initial stages of establishing distribution networks [33][34] Question: What is the company's cash flow situation and burn rate? - The company has $11.9 million in cash, with a cash runway expected to last through Q2 2026; cost reductions are in place without impacting key development programs [39][40]

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and ...

Journey Medical Corporation (NASDAQ:DERM) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Bra ...

MicroVision, Inc. (NASDAQ:MVIS) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Drew Markham - General Counsel Sumit Sharma - CEO Glen DeVos - CTO Anubhav Verma - CFO Conference Call Participants Casey Ryan - Westpark Capital Jesse Sobelson - D. Boral Capital Operator Good afternoon, and welcome to the MicroVision Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. At the end of today's p ...

Investcorp Credit Management BDC (ICMB) Q2 2025 Earnings Call March 26, 2025 07:00 PM ET Company Participants Walter Tsin - Principal & CFOSuhail Shaikh - CEO, CIO of Private Credit & DirectorChristopher Nolan - Senior VP - Equity Research Walter Tsin And Chief Executive Officer of the company. I would like to remind everybody that today's call is being recorded and that this call is the property of Industrial Credit Management, BDC. Any unauthorized broadcast of this call in any form is strictly prohibited ...